Helper cell-independent antitumor activity of potent CD8⁺ T cell epitope peptide vaccines is dependent upon CD40L

References

• Vacchelli E, Martins I, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Peptide vaccines in cancer therapy. Oncoimmunology 2012; 1:1557 - 76; http://dx.doi.org/10.4161/onci.22428; PMID: 23264902
   PubMed Web of Science ®Google Scholar
• Tindle RW, Fernando GJ, Sterling JC, Frazer IHA. A “public” T-helper epitope of the E7 transforming protein of human papillomavirus 16 provides cognate help for several E7 B-cell epitopes from cervical cancer-associated human papillomavirus genotypes. Proc Natl Acad Sci U S A 1991; 88:5887 - 91; http://dx.doi.org/10.1073/pnas.88.13.5887; PMID: 1712110
   PubMed Web of Science ®Google Scholar
• Feltkamp MC, Smits HL, Vierboom MP, Minnaar RP, de Jongh BM, Drijfhout JW, ter Schegget J, Melief CJ, Kast WM. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 1993; 23:2242 - 9; http://dx.doi.org/10.1002/eji.1830230929; PMID: 7690326
   PubMed Web of Science ®Google Scholar
• Ridge JP, Di Rosa F, Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 1998; 393:474 - 8; http://dx.doi.org/10.1038/30989; PMID: 9624003
   PubMed Web of Science ®Google Scholar
• Franco A, Tilly DA, Gramaglia I, Croft M, Cipolla L, Meldal M, Grey HM. Epitope affinity for MHC class I determines helper requirement for CTL priming. Nat Immunol 2000; 1:145 - 50; http://dx.doi.org/10.1038/77827; PMID: 11248807
   PubMed Web of Science ®Google Scholar
• Jäeger E, Bernhard H, Romero P, Ringhoffer M, Arand M, Karbach J, Ilsemann C, Hagedorn M, Knuth A. Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanoma-associated antigens. Int J Cancer 1996; 66:162 - 9; http://dx.doi.org/10.1002/(SICI)1097-0215(19960410)66:2<162::AID-IJC4>3.0.CO;2-0; PMID: 8603805
   PubMed Web of Science ®Google Scholar
• Salgaller ML, Marincola FM, Cormier JN, Rosenberg SA. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res 1996; 56:4749 - 57; PMID: 8840994
   PubMed Web of Science ®Google Scholar
• Pass HA, Schwarz SL, Wunderlich JR, Rosenberg SA. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay. Cancer J Sci Am 1998; 4:316 - 23; PMID: 9815296
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998; 4:321 - 7; http://dx.doi.org/10.1038/nm0398-321; PMID: 9500606
   PubMed Web of Science ®Google Scholar
• Jäger E, Gnjatic S, Nagata Y, Stockert E, Jäger D, Karbach J, Neumann A, Rieckenberg J, Chen YT, Ritter G, et al. Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc Natl Acad Sci U S A 2000; 97:12198 - 203; http://dx.doi.org/10.1073/pnas.220413497; PMID: 11027314
   PubMed Web of Science ®Google Scholar
• Muderspach L, Wilczynski S, Roman L, Bade L, Felix J, Small LA, Kast WM, Fascio G, Marty V, Weber J. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin Cancer Res 2000; 6:3406 - 16; PMID: 10999722
   PubMed Web of Science ®Google Scholar
• Weber J, Sondak VK, Scotland R, Phillip R, Wang F, Rubio V, Stuge TB, Groshen SG, Gee C, Jeffery GG, et al. Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma. Cancer 2003; 97:186 - 200; http://dx.doi.org/10.1002/cncr.11045; PMID: 12491520
   PubMed Web of Science ®Google Scholar
• Liénard D, Rimoldi D, Marchand M, Dietrich PY, van Baren N, Geldhof C, Batard P, Guillaume P, Ayyoub M, Pittet MJ, et al. Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA. Cancer Immun 2004; 4:4; PMID: 15149168
   PubMedGoogle Scholar
• Cormier JN, Salgaller ML, Prevette T, Barracchini KC, Rivoltini L, Restifo NP, Rosenberg SA, Marincola FM. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J Sci Am 1997; 3:37 - 44; PMID: 9072306
   PubMed Web of Science ®Google Scholar
• Heath WR, Kjer-Nielsen L, Hoffmann MW. Avidity for antigen can influence the helper dependence of CD8+ T lymphocytes. J Immunol 1993; 151:5993 - 6001; PMID: 8245444
   PubMed Web of Science ®Google Scholar
• Wiesel M, Kratky W, Oxenius A. Type I IFN substitutes for T cell help during viral infections. J Immunol 2011; 186:754 - 63; http://dx.doi.org/10.4049/jimmunol.1003166; PMID: 21160039
   PubMed Web of Science ®Google Scholar
• Wang B, Norbury CC, Greenwood R, Bennink JR, Yewdell JW, Frelinger JA. Multiple paths for activation of naive CD8+ T cells: CD4-independent help. J Immunol 2001; 167:1283 - 9; PMID: 11466344
   PubMed Web of Science ®Google Scholar
• Mintern JD, Davey GM, Belz GT, Carbone FR, Heath WR. Cutting edge: precursor frequency affects the helper dependence of cytotoxic T cells. J Immunol 2002; 168:977 - 80; PMID: 11801627
   PubMed Web of Science ®Google Scholar
• Casares N, Lasarte JJ, de Cerio AL, Sarobe P, Ruiz M, Melero I, Prieto J, Borrás-Cuesta F. Immunization with a tumor-associated CTL epitope plus a tumor-related or unrelated Th1 helper peptide elicits protective CTL immunity. Eur J Immunol 2001; 31:1780 - 9; http://dx.doi.org/10.1002/1521-4141(200106)31:6<1780::AID-IMMU1780>3.0.CO;2-I; PMID: 11385623
   PubMed Web of Science ®Google Scholar
• Slansky JE, Rattis FM, Boyd LF, Fahmy T, Jaffee EM, Schneck JP, Margulies DH, Pardoll DM. Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. Immunity 2000; 13:529 - 38; http://dx.doi.org/10.1016/S1074-7613(00)00052-2; PMID: 11070171
   PubMed Web of Science ®Google Scholar
• Casares N, Arribillaga L, Sarobe P, Dotor J, Lopez-Diaz de Cerio A, Melero I, Prieto J, Borrás-Cuesta F, Lasarte JJ. CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination. J Immunol 2003; 171:5931 - 9; PMID: 14634104
   PubMed Web of Science ®Google Scholar
• Ahlers JD, Belyakov IM, Thomas EK, Berzofsky JA. High-affinity T helper epitope induces complementary helper and APC polarization, increased CTL, and protection against viral infection. J Clin Invest 2001; 108:1677 - 85; PMID: 11733563
   PubMed Web of Science ®Google Scholar
• Lasarte JJ, Sarobe P, Gullón A, Prieto J, Borrás-Cuesta F. Induction of cytotoxic T lymphocytes in mice against the principal neutralizing domain of HIV-1 by immunization with an engineered T-cytotoxic-T-helper synthetic peptide construct. Cell Immunol 1992; 141:211 - 8; http://dx.doi.org/10.1016/0008-8749(92)90140-K; PMID: 1532538
   PubMed Web of Science ®Google Scholar
• Shirai M, Pendleton CD, Ahlers J, Takeshita T, Newman M, Berzofsky JA. Helper-cytotoxic T lymphocyte (CTL) determinant linkage required for priming of anti-HIV CD8+ CTL in vivo with peptide vaccine constructs. J Immunol 1994; 152:549 - 56; PMID: 8283036
   PubMed Web of Science ®Google Scholar
• Valmori D, Fonteneau JF, Lizana CM, Gervois N, Liénard D, Rimoldi D, Jongeneel V, Jotereau F, Cerottini JC, Romero P. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J Immunol 1998; 160:1750 - 8; PMID: 9469433
   PubMed Web of Science ®Google Scholar
• Skipper JC, Hendrickson RC, Gulden PH, Brichard V, Van Pel A, Chen Y, Shabanowitz J, Wolfel T, Slingluff CL Jr., Boon T, et al. An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins. J Exp Med 1996; 183:527 - 34; http://dx.doi.org/10.1084/jem.183.2.527; PMID: 8627164
   PubMed Web of Science ®Google Scholar
• Malek TR. T helper cells, IL-2 and the generation of cytotoxic T-cell responses. Trends Immunol 2002; 23:465 - 7; http://dx.doi.org/10.1016/S1471-4906(02)02308-6; PMID: 12297409
   PubMed Web of Science ®Google Scholar
• Roy M, Waldschmidt T, Aruffo A, Ledbetter JA, Noelle RJ. The regulation of the expression of gp39, the CD40 ligand, on normal and cloned CD4+ T cells. J Immunol 1993; 151:2497 - 510; PMID: 8103067
   PubMed Web of Science ®Google Scholar
• Cronin DC 2nd, Stack R, Fitch FW. IL-4-producing CD8+ T cell clones can provide B cell help. J Immunol 1995; 154:3118 - 27; PMID: 7897202
   PubMed Web of Science ®Google Scholar
• Hernandez MG, Shen L, Rock KL. CD40-CD40 ligand interaction between dendritic cells and CD8+ T cells is needed to stimulate maximal T cell responses in the absence of CD4+ T cell help. J Immunol 2007; 178:2844 - 52; PMID: 17312128
   PubMed Web of Science ®Google Scholar
• Wong KL, Lew FC, MacAry PA, Kemeny DM. CD40L-expressing CD8 T cells prime CD8alpha(+) DC for IL-12p70 production. Eur J Immunol 2008; 38:2251 - 62; http://dx.doi.org/10.1002/eji.200838199; PMID: 18600823
   PubMed Web of Science ®Google Scholar
• Stark R, Hartung A, Zehn D, Frentsch M, Thiel A. IL-12-mediated STAT4 signaling and TCR signal strength cooperate in the induction of CD40L in human and mouse CD8+ T cells. Eur J Immunol 2013; 43:1511 - 7; http://dx.doi.org/10.1002/eji.201243218; PMID: 23765345
   PubMed Web of Science ®Google Scholar
• Min L, Mohammad Isa SA, Shuai W, Piang CB, Nih FW, Kotaka M, Ruedl C. Cutting edge: granulocyte-macrophage colony-stimulating factor is the major CD8+ T cell-derived licensing factor for dendritic cell activation. J Immunol 2010; 184:4625 - 9; http://dx.doi.org/10.4049/jimmunol.0903873; PMID: 20357255
   PubMed Web of Science ®Google Scholar
• Cho HI, Barrios K, Lee YR, Linowski AK, Celis E. BiVax: a peptide/poly-IC subunit vaccine that mimics an acute infection elicits vast and effective anti-tumor CD8 T-cell responses. Cancer Immunol Immunother 2013; 62:787 - 99; http://dx.doi.org/10.1007/s00262-012-1382-6; PMID: 23266830
   PubMed Web of Science ®Google Scholar
• Bourgeois C, Rocha B, Tanchot C. A role for CD40 expression on CD8+ T cells in the generation of CD8+ T cell memory. Science 2002; 297:2060 - 3; http://dx.doi.org/10.1126/science.1072615; PMID: 12242444
   PubMed Web of Science ®Google Scholar
• Xydia M, Ge Y, Quitsch U, Beckhove P. CD40L co-stimulation from CD8+ to CD4+ effector memory T cells supports CD4+ expansion. Immunol Cell Biol 2011; 89:670 - 80; http://dx.doi.org/10.1038/icb.2010.153; PMID: 21151195
   PubMed Web of Science ®Google Scholar
• de Goër de Herve MG, Dembele B, Vallée M, Herr F, Cariou A, Taoufik Y. Direct CD4 help provision following interaction of memory CD4 and CD8 T cells with distinct antigen-presenting dendritic cells. J Immunol 2010; 185:1028 - 36; http://dx.doi.org/10.4049/jimmunol.0904209; PMID: 20562265
   PubMed Web of Science ®Google Scholar
• Nakamura Y, Watchmaker P, Urban J, Sheridan B, Giermasz A, Nishimura F, Sasaki K, Cumberland R, Muthuswamy R, Mailliard RB, et al. Helper function of memory CD8+ T cells: heterologous CD8+ T cells support the induction of therapeutic cancer immunity. Cancer Res 2007; 67:10012 - 8; http://dx.doi.org/10.1158/0008-5472.CAN-07-1735; PMID: 17942935
   PubMed Web of Science ®Google Scholar
• Frentsch M, Stark R, Matzmohr N, Meier S, Durlanik S, Schulz AR, Stervbo U, Jürchott K, Gebhardt F, Heine G, et al. CD40L expression permits CD8+ T cells to execute immunologic helper functions. Blood 2013; 122:405 - 12; http://dx.doi.org/10.1182/blood-2013-02-483586; PMID: 23719298
   PubMed Web of Science ®Google Scholar
• Speiser DE, Pittet MJ, Rimoldi D, Guillaume P, Luescher IF, Liénard D, Lejeune F, Cerottini JC, Romero P. Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor-specific T cells. Semin Cancer Biol 2003; 13:461 - 72; http://dx.doi.org/10.1016/j.semcancer.2003.09.010; PMID: 15001165
   PubMed Web of Science ®Google Scholar
• Pascolo S, Bervas N, Ure JM, Smith AG, Lemonnier FA, Pérarnau B. HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice. J Exp Med 1997; 185:2043 - 51; http://dx.doi.org/10.1084/jem.185.12.2043; PMID: 9182675
   PubMed Web of Science ®Google Scholar
• Echeverria I, Pereboev A, Silva L, Zabaleta A, Riezu-Boj JI, Bes M, Cubero M, Borras-Cuesta F, Lasarte JJ, Esteban JI, et al. Enhanced T cell responses against hepatitis C virus by ex vivo targeting of adenoviral particles to dendritic cells. Hepatology 2011; 54:28 - 37; http://dx.doi.org/10.1002/hep.24325; PMID: 21452282
   PubMed Web of Science ®Google Scholar